Resources

In this blog, NRG Therapeutics co-founder and CEO Dr Neil Miller and Parkinson’s UK Director of Research (and Investor Observer to NRG), Professor David Dexter, explore the history of the relationship and the innovation journey to date.

In this blog, Tom Sheldon, Senior Manager at the Science Media Centre (SMC), explores how scientists and communicators are taking on misinformation head-on — and how the SMC’s work supports both researchers and journalists in helping the public make sense of complex, and sometimes controversial, scientific issues.

Ellie Avni, Senior Director in Employment Tax and Reward at FTI Consulting, explores how the new PISCES platform could reshape EMI and CSOP share option plans – creating fresh opportunities for flexibility and tax-efficient value realisation.

In this blog, Ivana Visnjic-Lynch, Marketing Manager at ZAGENO, discusses the race for breakthrough therapies and the need for  effective R&D spend management which enables technology to unlock the future.

In the last week, we have been hit by headlines that MSD plans to close its discovery research activities in London and that AstraZeneca is pausing investment due to the UK commercial environment and specifically in response to VPAG outcomes.

In the third part of our series on Industrial Strategy, Lewis Miles and Maddie Cass provide a deep dive into the Digital and Technologies Sector Plan, analysing how these policies aim to foster growth in the UK's life sciences and engineering biology sectors. We also look forward to strengthening relations and gaining key insight from our US sister organisation with BIO's upcoming UK visit.

In my final summer update as BIA CEO, I reflect on 12 amazing years and look ahead to my new role as Executive Chair of the Office for Life Sciences. This week we’ve also published our latest finance report, and we’re hiring - so if you’re looking for your next challenge, now’s the time to join Team BIA.

Construction of Europe’s tallest and most technically sophisticated purpose-built commercial lab building has started on site at Canary Wharf, London.

BIA welcomed the focus on life sciences SMEs, engineering biology, and the measures designed to help high-growth companies scale and remain rooted in the UK.

From a multi-billion-pound boost to R&D and life sciences manufacturing, to scaling innovative businesses through the British Business Bank, the Review signals significant investment.

Positive news ahead of Spending Review (join our webinar this Friday), latest on getting pensions investment into UK life sciences and more!

Pension capital is unlocked in time for BIA's Parliament Day this Wednesday.

We are heading to Boston this June for the BIO International Convention 2025 – one of the world’s largest and most influential gatherings in the life sciences calendar. 

This is a move that speaks to the strength of BIA and the vitality of the UK life sciences ecosystem.